三七粉胶囊辅助治疗缺血性卒中的临床疗效及其对铁死亡相关蛋白的影响  

Clinical Efficacy of Sanqi Powder Capsules in Adjuvant Treatment of Ischemic Stroke and Its Effect on Ferroptosis-Related Protein

作　　者：刘莹莹[1] 王国军 LIU Yingying;WANG Guojun(Department of Neurology,Affiliated Hospital of Yan'an University,Yan'an 716000,China;Department of Rehabilitation Medicine,Cardiovascular and Cerebrovascular Disease Hospital,Yan'an University Affiliated Hospital,Yan'an 716000,China)

机构地区：[1]延安大学附属医院神经内科,陕西省延安市716000 [2]延安大学附属医院心脑血管病医院康复医学科,陕西省延安市716000

出　　处：《实用心脑肺血管病杂志》2024年第9期81-85,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：延安大学附属医院科学技术研究发展计划项目(2022PT-34);陕西省卫生健康委员会科研项目(S20220113)。

摘　　要：目的探讨三七粉胶囊辅助治疗缺血性卒中的临床疗效及其对铁死亡相关蛋白的影响。方法本研究为双盲、安慰剂对照的随机试验。选取2022年1月—2023年6月在延安大学附属医院收治的150例缺血性卒中患者作为研究对象。采用随机数字表法将患者分为对照组和观察组,每组75例。两组患者均接受再灌注治疗或常规药物治疗,在此基础上,对照组患者口服安慰剂,观察组患者口服三七粉胶囊,两组患者均持续治疗3个月。记录患者治疗3个月功能独立者占比,治疗前后美国国立卫生研究院卒中量表(NIHSS)评分及其差值(∆NIHSS评分),治疗前后铁死亡相关蛋白[血浆可溶性转铁蛋白受体(sTfR)、同型半胱氨酸(Hcy)、4-羟壬二酸酯(4-HNE)水平]及其差值(∆sTfR、∆Hcy、∆4-HNE),治疗3个月内卒中复发率、复合脑血管事件发生率。结果治疗3个月,观察组功能独立者占比高于对照组(P<0.05)。观察组治疗后NIHSS评分、∆NIHSS评分低于对照组(P<0.05)。观察组治疗后血浆sTfR水平、∆sTfR高于对照组,治疗后血浆4-HNE水平、∆4-HNE低于对照组(P<0.05)。功能独立者治疗后血浆sTfR水平、∆sTfR高于非功能独立者,治疗后血浆4-HNE水平、∆4-HNE低于非功能独立者(P<0.05)。治疗3个月内,两组卒中复发率、复合脑血管事件发生率比较,差异无统计学意义(P>0.05)。结论三七粉胶囊辅助治疗能有效促进缺血性卒中患者功能独立,减轻神经功能损伤程度,提高血浆sTfR水平,降低血浆4-HNE水平,且未增加卒中复发风险及复合脑血管事件发生风险;三七粉胶囊辅助治疗促进缺血性卒中患者功能独立的机制可能与其升高血浆sTfR水平、降低血浆4-HNE水平有关。Objective To investigate the clinical efficacy of Sanqi powder capsule in the adjuvant treatment of ischemic stroke and its effect on ferroptosis-related protein.Methods This study was a double-blind,placebo-controlled randomized trial.A total of 150 patients with ischemic stroke admitted to Affiliated Hospital of Yan'an University from January 2022 to June 2023 were selected as the study subjects.The patients were divided into control group and observation group by random number table method,with 75 cases in each group.Patients in both groups received reperfusion therapy or conventional drug therapy.On this basis,patients in the control group were given placebo,and patients in the observation group were treated with Sanqi powder capsules.Patients in both groups were treated for 3 months.The proportion of patients with functional independence at 3 months of treatment,the National Institutes of Health Stroke Scale(NIHSS)score before and after treatment and its difference(∆NIHSS score),ferroptosis-related protein[the level of plasma soluble transferrin receptor(sTfR),homocysteine(Hcy),4-hydroxynonanedioate(4-HNE)]before and after treatment and their differences(∆sTfR,∆Hcy,∆4-HNE),the recurrence rate of stroke and the incidence of compound cerebrovascular events within 3 months of treatment were recorded.Results At 3 months after treatment,the proportion of patients with functional independence in the observation group was higher than that in the control group(P<0.05).The NIHSS score after treatment and∆NIHSS score in the observation group were lower than those in the control group(P<0.05).The plasma sTfR level after treatment and∆sTfR in the observation group were higher than those in the control group,and the plasma 4-HNE level after treatment and∆4-HNE were lower than those in the control group(P<0.05).The plasma sTfR level after treatment and∆sTfR in patients with functional independence were higher than those in patients with non-functional independence,and the plasma 4-HNE level after treatment

关 键 词：缺血性卒中 三七粉胶囊 铁死亡 治疗结果 临床对照试验 

分 类 号：R743.3[医药卫生—神经病学与精神病学]